FDA
-
-
-
-
-
-
-
Pacira BioSciences Reports First Quarter 2026 Financial Results
-
-
-
-
-
-
-
Pacira BioSciences reports favorable outcomes for iovera device in back pain study
-
-
-
-
-
-
-
Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee
-
-
-
-
-
-
-
Pacira BioSciences Reports Second Quarter 2025 Financial Results
-
-
-
-
-
-
-
Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis
-
-
-
-
-
-
-
Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results
-
-
-
-
-
-
-
RBC Capital's Game Changers: 'Disruptive Forces in Biotech'
-
324,655 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

